Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Biomarker-directed Phase 2 Platform Study in Patients With Advanced Non-Small Lung Cancer Whose Disease Has Progressed on First-Line Osimertinib Therapy.

NCT03944772 is registered in ClinicalTrials.gov with AstraZeneca as lead sponsor.

NCT NCT03944772
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT03944772 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Biomarker-directed Phase 2 Platform Study in Patients With Advanced Non-Small Lung Cancer Whose Disease Has Progressed on First-Line Osimertinib Therapy.
Lead sponsor
AstraZeneca
Phase
Phase 2
Overall status
Active, not recruiting
Start date
June 25, 2019
Completion date
May 6, 2025
Enrollment
247 (actual)
Sites
47

Conditions

As the registry lists them; a condition with its own page is linked.

non-small cell lung cancer